Scalper1 News
Though still in its early days, Gilead Sciences’ hepatitis C drug Sovaldi may be enjoying one of the most massive drug launches of all time. Current consensus calls for sales of $4.6 billion this year — and the whisper numbers are running even higher. This doesn’t surprise Wall Street, as Sovaldi provides a faster, safer and stronger alternative to a punishing year-long regimen of interferon. But as analysts obsessively watch the weekly Scalper1 News
Scalper1 News